Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15723748 | 0.84 | GRM1 (0.37) | NTRK1LRRK2GRM1CYP1A2EED | |
| SCHEMBL15723735 | 0.81 | NTRK1 (0.37) | NTRK1LRRK2CYP1A2IRAK4ACHE | |
| SCHEMBL13194751 | 0.81 | LRRK2 (0.37) | NTRK1LRRK2GRM1CYP1A2ACHE | |
| SCHEMBL15723756 | 0.81 | GRM1 (0.39) | NTRK1LRRK2GRM1EEDIRAK4 | |
| SCHEMBL23501964 | 0.80 | LRRK2 (0.36) | NTRK1LRRK2CYP1A2ACHE | |
| SCHEMBL3905037 | 0.80 | GRIA2 (0.38) | NTRK1LRRK2CYP1A2IRAK4ACHE | |
| SCHEMBL13598334 | 0.80 | LRRK2 (0.39) | NTRK1LRRK2CYP1A2ACHEADORA3 | |
| SCHEMBL12985053 | 0.79 | LRRK2 (0.34) | NTRK1LRRK2 | |
| SCHEMBL15724398 | 0.79 | LRRK2 (0.36) | NTRK1LRRK2CYP1A2ACHE | |
| SCHEMBL14555389 | 0.78 | LMNA (0.40) | LRRK2GRM1CYP1A2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | NTRK1 4882/4885LRRK2 1138/4885GRM1 4264/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | NTRK1 4882/4885LRRK2 1138/4885GRM1 4264/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | NTRK1 4882/4885LRRK2 1138/4885GRM1 4264/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | NTRK1 4882/4885LRRK2 1138/4885GRM1 4264/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | NTRK1 4882/4885LRRK2 1138/4885GRM1 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.